アテロコラーゲンsiRNA導入技術のRNAi医薬への応用  [in Japanese] Application of Atelocollagen-mediated siRNA Delivery for RNAi Therapies  [in Japanese]

Access this Article

Author(s)

    • 本間 紀美 HONMA Kimi
    • 国立がんセンター研究所がん転移研究室 Section for Studies on Metastasis, National Cancer Center Research Institute
    • 落谷 孝広 OCHIYA Takahiro
    • 国立がんセンター研究所がん転移研究室 Section for Studies on Metastasis, National Cancer Center Research Institute

Abstract

  RNAi has rapidly become a powerful tool for drug target discovery and validation in an <i>in vitro</i> culture system and, consequently, interest is rapidly growing for extension of its application to <i>in vivo</i> systems, such as animal disease models and human therapeutics. Novel treatments and drug discovery in pre-clinical studies based on RNAi are currently targeting a wide range of diseases, including viral infections and cancers by the local administration of synthetic small interfering RNA (siRNA) that target local lesions. Recently, specific methods for the systemic administration of siRNAs have been reported to treat non-human primates or a cancer metastasis model. <i>In vivo</i> siRNA-delivery technology is a key hurdle to the successful therapeutic application of RNAi. This article reviews the non-viral delivery system of atelocollagen for siRNA, which could be useful for functional screening of the genes <i>in vitro</i> and <i>in vivo</i>, and will provide a foundation for further development of RNAi therapeutics.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 127(5), 807-812, 2007-05-01

    The Pharmaceutical Society of Japan

References:  20

Cited by:  1

Codes

  • NII Article ID (NAID)
    110006273925
  • NII NACSIS-CAT ID (NCID)
    AN00284903
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    00316903
  • NDL Article ID
    8813091
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z19-411
  • Data Source
    CJP  CJPref  NDL  NII-ELS  J-STAGE 
Page Top